NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Anti-malaria MAb in Malian Children

Phase 2

Completed

Conditions: Plasmodium Falciparum Infection
Malaria

Interventions: Biological: L9LS (VRC-MALMAB0114-00-AB) Subcutaneous injection
Other: Placebo
Biological: L9LS (VRC-MALMAB0114-00-AB) intravenous injection

First Posted Date: 2022-03-31

Last Posted Date: 2024-07-10

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 365

Registration Number: NCT05304611

Locations: 🇲🇱
Torodo MRTC Clinic, Torodo, Région De Koulikoro, Mali
🇲🇱
Kalifabougou MRTC Clinic, Kalifabougou, Région De Koulikoro, Mali

Safety, Tolerability, and Immunogenicity Study of Sm-p80 + GLA-SE (SchistoShield(R)) Vaccine in Healthy Adults

Phase 1

Completed

Conditions: Schistosomiasis

Interventions: Biological: Sm-p80 + GLA-SE
Biological: Sm-p80

First Posted Date: 2022-03-23

Last Posted Date: 2024-12-17

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 45

Registration Number: NCT05292391

Locations: 🇺🇸
Kaiser Permanente Washington Health Research Institute, Seattle, Washington, United States

COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)

Phase 2

Completed

Conditions: COVID-19

Interventions: Biological: mRNA-1273.351
Biological: mRNA-1273
Biological: BNT162b2 (B.1.1.529)
Biological: BNT162b2
Drug: AS03
Biological: BNT162b2 bivalent (wildtype and Omicron BA.1)
Biological: BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5)
Other: Sodium Chloride, 0.9%
Biological: mRNA-1273.529
Biological: mRNA-1273.617.2
Biological: BNT162b2 (B.1.351)
Biological: CoV2 preS dTM/D614
Biological: CoV2 preS dTM [B.1.351]
Biological: CoV2 preS dTM/D614+B.1.351

First Posted Date: 2022-03-21

Last Posted Date: 2024-08-13

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 1270

Registration Number: NCT05289037

Locations: 🇺🇸
University of Texas Medical Branch, League City, Texas, United States
🇺🇸
Tulane University Clinical Translational Unit, New Orleans, Louisiana, United States
🇺🇸
Washington University School of Medicine in St. Louis - Infectious Disease Clinical Research Unit, Saint Louis, Missouri, United States

and more 17 locations

Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

Phase 4

Recruiting

Conditions: Multiple Sclerosis

Interventions: Drug: Ocrelizumab
Drug: Placebo for Ocrelizumab

First Posted Date: 2022-03-18

Last Posted Date: 2024-12-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 123

Registration Number: NCT05285891

Locations: 🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States
🇺🇸
MedStar Georgetown University Hospital, Washington, District of Columbia, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 8 locations

Registry of Asthma Characterization and Recruitment 3 (RACR3)

Recruiting

Conditions: Asthma

First Posted Date: 2022-03-09

Last Posted Date: 2024-06-26

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 1500

Registration Number: NCT05272241

Locations: 🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago: Division of Allergy and Immunology, Chicago, Illinois, United States
🇺🇸
Boston Children's Hospital: Department of Immunology, Boston, Massachusetts, United States
🇺🇸
Children's Hospital Colorado: Allergy Program, Aurora, Colorado, United States

and more 4 locations

Respiratory Virus Sampling and Repository

Recruiting

Conditions: Influenza
COVID-19

First Posted Date: 2022-03-04

Last Posted Date: 2023-10-12

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 20000

Registration Number: NCT05266222

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸
NIH Building 33 (NIAID), Bethesda, Maryland, United States

A Clinical Trial to Evaluate the Safety and Immunogenicity of BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV Trimer mRNA Vaccines in Healthy, HIV-uninfected Adult Participants

Phase 1

Active, not recruiting

Conditions: HIV Infections

Interventions: Biological: BG505 MD39.3 gp151 CD4KO mRNA
Biological: BG505 MD39.3 mRNA
Biological: BG505 MD39.3 gp151 mRNA

First Posted Date: 2022-02-01

Last Posted Date: 2024-10-31

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 108

Registration Number: NCT05217641

Locations: 🇺🇸
University of Rochester Vaccines to Prevent HIV Infection CRS [31467], Rochester, New York, United States
🇺🇸
Columbia P&S CRS [30329], New York, New York, United States
🇺🇸
Alabama CRS [31788], Birmingham, Alabama, United States

and more 7 locations

VIBRANT: VIB4920 for Active Lupus Nephritis

Phase 2

Recruiting

Conditions: Lupus Nephritis

Interventions: Drug: Placebo for VIB4920
Drug: VIB4920

First Posted Date: 2022-01-21

Last Posted Date: 2024-12-18

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 74

Registration Number: NCT05201469

Locations: 🇺🇸
University of California San Diego School of Medicine: Division of Rheumatology, Allergy and Immunology, La Jolla, California, United States
🇺🇸
UCLA Medical Center: Division of Rheumatology, Los Angeles, California, United States
🇺🇸
University of California, Irvine School of Medicine Division of Rheumatology, Orange, California, United States

and more 14 locations

NADPH Oxidase Correction in mRNA-transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)

Phase 1

Recruiting

Conditions: Infection
Chronic Granulomatous Disease

Interventions: Biological: gp91 Grans

First Posted Date: 2022-01-13

Last Posted Date: 2024-12-27

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 25

Registration Number: NCT05189925

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

A Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of PGDM1400LS Alone and in Combination With VRC07-523LS and PGT121.414.LS in Healthy, HIV-uninfected Adult Participants

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: PGDM1400LS (5mg/kg, IV)
Drug: PGDM1400LS (20mg/kg, IV)
Drug: PGDM1400LS (20mg/kg, SC)
Drug: PGDM1400LS (40mg/kg, IV)
Drug: PGDM1400LS (40mg/kg, SC)
Drug: PGDM1400LS (1.4g, IV)
Drug: PGDM1400LS (1.4g, SC)
Drug: VRC07-523LS (20mg/kg, IV)
Drug: VRC07-523LS (20mg/kg, SC)
Drug: VRC07-523LS (1.4g, IV)
Drug: VRC07-523LS (40mg/kg, IV)
Drug: VRC07-523LS (1.4g, SC)
Drug: PGT121.414.LS (20mg/kg, IV)
Drug: PGT121.414.LS (20mg/kg, SC)
Drug: PGT121.414.LS (40mg/kg, IV)
Drug: PGT121.414.LS (1.4g, IV)
Drug: PGT121.414.LS (1.4g, SC)

First Posted Date: 2022-01-11

Last Posted Date: 2024-03-13

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 95

Registration Number: NCT05184452

Locations: 🇺🇸
George Washington University, Washington, District of Columbia, United States
🇺🇸
Bridge HIV CRS, San Francisco, California, United States
🇺🇸
The Hope Clinic of the Emory Vaccine Center, Atlanta, Georgia, United States

and more 10 locations

Home Terms & Conditions Privacy Policy